LNTH Lantheus Holdings, Inc.
USHealthcareAs of 2026-07-10 16:00
Why LNTH matters now
Lantheus Holdings, Inc. (LNTH) is a US stock in Healthcare. The latest InvestLog snapshot shows $105.64 with -0.33% on the session and $6.88B in market capitalization; recent performance reads 1-month +11.81% and YTD +56.06%.
The latest financial table shown here is Q1 2026, with revenue of $377.3M, net income of $118.4M, and EPS of $1.80. Investors can compare that operating picture with valuation signals such as P/E 22.46 and FCF yield 5.5%.
The latest indexable market news headline is "FDA Manufacturing Issues Delay Lantheus' Tumor Imaging Kit" from Benzinga.
Additional event context on this page matters because analyst consensus is Buy with a median target of $112.50; recent insider activity includes EASTLAND JULIA MARIE filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
22.46
PEG
—
P/B
5.55
P/S
4.37
EV/EBITDA
14.58
DCF Value
$826.61
FCF Yield
5.5%
Div Yield
0.0%
Margins & Returns
Gross Margin
60.5%
Operating Margin
18.8%
Net Margin
18.0%
ROE
24.3%
ROA
11.9%
ROIC
10.8%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $377.3M | $118.4M | $1.80 |
| Q4 2025 | $406.8M | $54.1M | $0.82 |
| FY 2025 | $1.54B | $233.6M | $3.41 |
| Q3 2025 | $384.0M | $27.8M | $0.41 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$108.50
Target (Median)
$112.50
Target Range
$94.00 - $115.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Country
US
Exchange
—
Beta
-0.04
Lantheus Holdings, Inc. is a global pharmaceutical company dedicated to the development, manufacturing, and commercialization of advanced diagnostic and therapeutic agents. Their mission is to empower clinicians worldwide in the accurate diagnosis and effective treatment of a wide spectrum of conditions, particularly heart disease, various cancers, and other serious illnesses. Their current diagnostic portfolio features several key products: DEFINITY, a microbubble ultrasound contrast agent for cardiac evaluations; TechneLite, a technetium generator essential for nuclear medicine; Xenon-133, used to assess pulmonary function; Neurolite, which helps identify stroke-damaged areas in the brain; Cardiolite, an injectable Tc-99m-labeled imaging agent; Thallium-201 for detecting cardiovascular disease; and Gallium-67, utilized in identifying infections and cancerous tumors. They also offer the Automated Bone Scan Index, a tool for quantifying prostate cancer burden from bone scans; PYLARIFY, designed for visualizing lymph nodes, bone, and soft tissue metastases to detect recurrent or metastatic prostate cancer; and Cobalt (Co 57), a non-pharmaceutical radiochemical. In the therapeutic space, Lantheus provides AZEDRA, a radiopharmaceutical treatment for both adult and pediatric patients, and RELISTOR, a medication addressing opioid-induced constipation. The company's robust development pipeline includes promising innovations such as flurpiridaz F 18, an agent for assessing myocardial blood flow; 1095, a PSMA-targeted iodine-131 labeled small molecule; LMI 1195 for neuroblastoma tumors in both children and adults; PYLARIFY AI, an AI-powered medical device software for standardized quantitative analysis of PSMA PET/CT images in prostate cancer; and leronlimab, an investigational humanized monoclonal antibody. Lantheus serves a diverse client base, including radiopharmacies, distributors, integrated delivery networks, hospitals, clinics, and group medical practices. They foster strategic collaborations with notable industry partners such as NanoMab Technology Limited, Bausch Health Companies, Inc., GE Healthcare Limited, Curium, Bayer AG, CytoDyn Inc., ROTOP, FUJIFILM, Regeneron Pharmaceuticals, Inc., and POINT Biopharma US Inc. Established in 1956, Lantheus Holdings, Inc. maintains its corporate headquarters in North Billerica, Massachusetts.